MYLAN-CIPROFLOXACIN 500 MG
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 500 MG · DIN 02245648 · MYLAN PHARMACEUTICALS ULC
Health Canada status: CANCELLED POST MARKET
What is MYLAN-CIPROFLOXACIN?
MYLAN-CIPROFLOXACIN 500 MG contains CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02245648, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 12-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYLAN-CIPROFLOXACIN used for?
Treatment of respiratory tract, urinary tract, skin/soft tissue, bone/joint infections, infectious diarrhea, meningococcal carriers, typhoid fever, and uncomplicated gonorrhea.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02245648 |
|---|---|
| Brand name | MYLAN-CIPROFLOXACIN |
| Generic / active ingredient | CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 500 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01MA02 CIPROFLOXACIN |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 12-Jul-2018 |
How is it administered?
Dose depends on severity of infection and renal function. Tablets should be swallowed whole with liquid. May be taken with or without meals. Avoid antacids/dairy at same time.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard summary table mentions nonmedicinal ingredients but not temperature).
How is it supplied?
Not explicitly detailed in provided text (mentions 250 mg and 500 mg strengths).
Contraindications
Hypersensitivity to ciprofloxacin or other quinolones; concurrent administration with agomelatine or tizanidine.
Warnings and precautions
Serious risks of tendonitis, tendon rupture, peripheral neuropathy, CNS effects (seizures), QT prolongation, and exacerbation of myasthenia gravis. Risk of hepatic failure and phototoxicity.
Is CIPROFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01MA02 CIPROFLOXACIN. 29 of 139 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT CIPROFLOXACIN | 250 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02247339 |
| ACT CIPROFLOXACIN | 500 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02247340 |
| ACT CIPROFLOXACIN | 750 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02247341 |
| AURO-CIPROFLOXACIN | 250 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02381907 |
| AURO-CIPROFLOXACIN | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02381923 |
| BIO-CIPROFLOXACIN | 500 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02444887 |
| CIPRO ORAL SUSPENSION | 500 MG / 5 ML | SUSPENSION | BAYER INC | MARKETED | DIN 02237514 |
| CIPROFLOXACIN | 250 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02353318 |
| CIPROFLOXACIN | 250 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02386119 |
| CIPROFLOXACIN | 500 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02353326 |
Who else supplies CIPROFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CIPROFLOXACIN appears in 449 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.